ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

olatorepatide

Also written as “Olatorepatide”, “HS-20094” and “HS-20094 Injection”.

Its studies are mostly in Obesity · Diabetes Mellitus, Type 2 · Hidradenitis Suppurativa · Overweight, led by 2 companies.

Drug pageOlatorepatide: every studyAll 4 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Feb 18, 202512 company-led studies, 7 open or runningLicense: Hansoh → Regeneron, Jun 2025Next primary completion: Mar 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hansoh Pharmaceutical Group83 open or runningphase 3since Feb 18, 2025Oct 29, 2021Mar 30, 2027phase 3 · NCT07156500
Regeneron Pharmaceuticalsits history only44 open or runningphase 3since Oct 19, 2026Feb 18, 2026Jan 21, 2028phase 2 · NCT07685808
  • Named in Hansoh Pharmaceutical Group’s own pipeline as Olatorepatide (HS-20094), phase 4, as of Aug 26, 2026 (source).

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Hansoh Pharmaceutical Group only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 29, 2021First study: phase 1 study in Diabetes Mellitus, Type 2First studyNCT05116410 · 68 enrolled · China
  2. May 25, 2023Phase 2 study in Diabetes Mellitus, Type 2NCT06118008 · 54 enrolled · China
  3. Oct 17, 2023Phase 2 study in OverweightNCT06118021 · 200 enrolled · China
  4. Feb 29, 2024Named olatorepatideINNProposed as its International Nonproprietary Name in WHO's List 130 · before, HS-20094
  5. Feb 18, 2025Phase 3 study in OverweightNCT06839664 · 604 enrolled · China
  6. Feb 25, 2025Phase 2 study in Diabetes Mellitus, Type 2NCT06901648 · 275 enrolled · China
  7. Jun 2, 2025Phase 1 study in OverweightNCT07057674 · 144 planned · China
  8. Jun 2, 2025Regeneron licensed it from HansohLicenseEverywhere outside mainland China, Hong Kong and Macau · announced · Regeneron
  9. Aug 28, 20252 phase 3 studies in Diabetes Mellitus, Type 2NCT07156539, NCT07156500

Ahead

  1. Mar 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07156539
  2. Mar 30, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 2NCT07156500

TargetBeta

“A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)”study text, read by Claude · the study

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
TirzepatideruleEli Lillyphase 472
retatrutideruleEli Lillyphase 333
brenipatideEli Lillyphase 319
UBT251The United Laboratories Internationalphase 312
enicepatideHoffmann-La Rochephase 310
VK2735ruleViking Therapeuticsphase 38
NNC0519-0130Novo Nordiskphase 211
BI 3034701Boehringer Ingelheimphase 26
HRS-4729Jiangsu HengRui Medicinephase 25
NA-931rulebiomed-industries-incphase 23

Studies

All 8 Hansoh Pharmaceutical Group leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07156539Diabetes Mellitus, Type 2 · China3Not yet recruitingMar 30, 2027546
NCT07156500Diabetes Mellitus, Type 2 · China3Not yet recruitingMar 30, 2027204
NCT07057674Overweight · China1RecruitingFeb 4, 2026144
NCT06901648Diabetes Mellitus, Type 2 · China2CompletedMar 7, 2025275
NCT06839664Overweight · China3CompletedJan 4, 2026604
NCT06118021Overweight · China2CompletedAug 13, 2024200
NCT06118008Diabetes Mellitus, Type 2 · China2CompletedJan 4, 202454
NCT05116410Diabetes Mellitus, Type 2 · China1UNKNOWNOct 31, 202268

How it is read

Names in the registry

  • “Olatorepatide”, 4 entries
  • “HS-20094”, 3 entries
  • “HS-20094 Injection”, 3 entries
  • “HS-20094 injection”, 1 entry
  • “HS-20094 5mg”, 1 entry

Codes read as this program: HS20094.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.